2014 Fiscal Year Final Research Report
The epigenetics of leukemic cell drug resistance
| Project/Area Number |
24791052
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 癌 / 遺伝子 / 発現制御 |
|---|
| Outline of Final Research Achievements |
We confirmed that the demethylating agent (decitabine) enhances the cytotoxic effect of anti-leukemic agents such as clofarabine and etoposide synergistically, and the cytotoxic effect is depend on caspase-3/7 activity. Then, we confirmed that decitabine increase mRNA expression levels of BID, BAX, BAD, PUMA, CASP3. Although, decitabine did not demethylate the CpG of BID, BAX, BAD, CASP3. Therefore, we carried out genome-wide gene expression studies and epigenome-wide association studies. The results showed that decitabine demethylate the CpG of AATK and increase its mRNA expression.
|
| Free Research Field |
小児血液学
|
